relationships demonstrate that addition of an acid group to dodecyl carbon chain, changing the cyclohexyl group to an adamantyl group, and shortening the carbon chain to two carbons all abolish the antiproliferative effect. Our finding that a highly selective urea-based inhibitor of sEH can alter biology independently of its putative target enzyme suggests that there may be other useful properties of this class of compounds unrelated to their influence on epoxyeicosanoids. In addition, our results show that caution should be used when attempting to infer conclusions of EET biology based solely on the effects these inhibitors in tissue culture models, especially when used at micromolar concentrations.
INTRODUCTION
Epoxyeicosatrienoic acids (EETs) are cytochrome P-450 metabolites of arachidonic acid with multiple biological functions, including (but not limited to) the regulation of vascular tone (Proctor et al., 1987; Gebremedhin et al., 1992; Carroll et al., 1993; Imig et al., 1996; Li et al., 1997; Imig et al., 1999) , renal tubular transport (Escalante et al., 1993) , cellular proliferation (Potente et al., 2003; Fleming et al., 2001; Potente et al., 2002) , and inflammation (Smith et al., 2005; Node et al., 1999) . EETs are converted by soluble epoxide hydrolase (sEH) into the corresponding dihydroxyeicosatrienoic acids (DHETs), and this conversion is one mechanism whereby EET biological effects are eliminated (Zeldin et al., 1993) . Inhibitors of sEH can mimic the biological effects of EETs by decreasing their metabolism by this enzyme (Yu et al., 2000; Imig et al., 2002; Zhao et al., 2004) . Due to the fact that some of these compounds can be administered in orally available formulations (Jung et al., 2005) , they are receiving increasing attention as potential pharmaceuticals for the treatment of hypertension, atherosclerosis, and inflammatory diseases.
The development of highly selective and systemically available urea-based inhibitors of sEH has greatly advanced the study of EET and sEH biology. In various studies, including many from our laboratories, these sEH inhibitors have been associated with attenuation of human vascular smooth muscle (HVSM) and endothelial cell proliferation in cultured cells (Davis et al., 2002) , reduction of blood pressure in spontaneously hypertensive animal models (Yu et al., 2000; Imig et al., 2002; Zhao et al., 2004) , and anti-inflammatory effects (Smith et al., 2005; Schmelzer K. et al., 2005) .
While these compounds appear to act directly through attenuation of sEH activity in JPET #91876 5 some cell systems (Fang et al., 2001) , in other situations, such as those described in this study, the biological response of the compounds at low micromolar concentrations is independent of inhibition of sEH.
We now show that CDU, which attenuates HVSM cell proliferation, does so independently of sEH inhibition and does not function through increased EET levels.
While we have yet to ascertain the precise mechanism of this growth-inhibitory effect, we report herein the first description of an sEH-independent effect by a compound in this class of selective and specific urea based sEH inhibitors. Our finding that a compound in this class of sEH inhibitors can alter biology independently of its putative target enzyme suggests that there may be other useful properties of this class of compounds unrelated to their influence on epoxyeicosanoids. In addition, our data indicates that caution should be used when attempting to infer conclusions of EET biology based solely on the effects these inhibitors, especially when they are used at micromolar concentrations in tissue culture models.
MATERIALS AND METHODS

Materials.
Human recombinant platelet-derived growth factor (PDGF)-BB and FGF-2 were obtained from Upstate Biotechnology (Lake Placid, NY). Mouse monoclonal β -actin was obtained from Sigma and used at a 1:4000 dilution. Polyclonal anti-sEH antibody against human sEH was raised from rabbits and has been described previously (Wixtrom et al., 1988) and was used at 1:2000 dilution. Horseradish peroxidaseconjugated anti-rabbit IgG and horseradish peroxidase-conjugated anti-mouse IgG was obtained from Bio-Rad and used at a 1:15000 dilution. Methyl-EETs were synthesized by oxidation of arachidonate acid methyl ester with meta-chloroperbenzoic acid (Gill and Hammock, 1979) followed by ester hydrolysis in dilute base following the procedures of Falck et al (Falck et al., 1990) . 11,12 and 14,15 EET regioisomers were purchased from Cayman Chemical (Ann Arbor, MI). sEH inhibitors were prepared previously in the laboratory and were dissolved in DMSO (Morisseau et al., 2002 (Weiss and Nuccitelli, 1992) .
Western Blots. Six centimeter plates of HVSM and HuH-7 cells were lysed, protein concentrations were determined by the Lowry method. Equal protein quantities were electrophoresed and Western-blotted as described (Weiss et al., 1998) . Nitrocellulose membranes were probed with anti-sEH antibody. To confirm equal protein loading blots were either reprobed with β -actin or equal amounts of lysates were loaded in duplicate lanes in the same gel and separated after transfer to be probed for β -actin separately.
sEH activity. sEH activity was determined using racemic [ 3 H]-trans-1,3-diphenylpropene oxide (tDPPO) as the substrate (Borhan et al., 1995 extraction after the addition of analytical surrogates and then were subsequently subjected to base hydrolysis. EET and DHET levels in the lipid extractions were then measured using a liquid chromatography tandem mass spectrometry (LC-MS) method (Newman et al., 2002) .
RESULTS
Attenuation of human VSM cell proliferation is independent of sEH inhibitor potency.
We have previously shown that incubation of HVSM or endothelial cells with CDU causes dose-dependent attenuation of proliferation, as assessed by [ 3 H]thymidine incorporation, with no apparent toxicity (Davis et al., 2002) . To extend this observation, we tested for HVSM anti-proliferative effects four novel sEH inhibitors that have similar or higher inhibition potency than CDU, as well as a urea based compound with minimal sEH inhibitory activity (Table) (Morisseau et al., 2002; Schmelzer et al., 2005; Jones et al., 2005) . Two of these compounds were used to test whether changes to the cyclohexyl moiety or the dodecyl moiety alter the anti-proliferative effects of these compounds.
ADU differs from CDU only in the replacement of the cyclohexyl group with an adamantyl group and CDUA only differs in the addition of an acid group to the dodecyl tail (Table) . The other two compounds were chosen because they are orally available sEH inhibitors that are excellent candidates for pharmaceutical use. Serum starved HVSM cells were stimulated with PDGF-BB in the presence or absence of the each specific sEH inhibitor for 24 h, and [ 3 H]thymidine incorporation was assessed. As previously reported (Davis et al., 2002) , CDU at 5µM reduces cells proliferation by approximately 50%
( Figure 1a) . Surprisingly, despite their potency with respect to sEH inhibition, the other sEH inhibitors 12-(3-cyclohexylureido)-dodecanoic acid (CUDA), 1-adamantyl-3-dodecyl urea (ADU), 12-(3-adamantylureido)-dodecanoic acid butyl ester (AUDA-BE),
1-adamantyl-3-(5-(2-(2-ethoxyethoxy)ethoxy)pentyl urea (950) do not inhibit HVSM cell proliferation at concentrations as high as 10µM, suggesting that the action of CDU is independent of sEH inhibition ( Figure 1a ).
To further examine the anti-proliferative effect of CDU we tested whether the hydrocarbon chain was required for this effect. We assessed the anti-proliferative effect of the relatively poor sEH inhibitor CEU, which differs from CDU in that an ethyl group is substituted for a dodecyl tail (see Table) . Using this compound, we found that the antiproliferative effects of CDU are abolished by the shortening the hydrocarbon chain to two carbons (CEU; Figure 1b ). Thus, the addition of a carboxylic acid group to the dodecyl tail (CUDA; Figure 1a PDGF-BB-stimulated foreskin fibroblasts (Davis et al., 2002) . Thus, the anti-proliferative effect of CDU is restricted to neither HVSM cells nor PDGF-BB.
EETs do not inhibit HVSM cell proliferation
We previously hypothesized that the anti-proliferative effect of CDU was a result of stabilization of EETs, such that the latter compound are the cellular agents inhibiting the proliferation of the cells (Davis et al., 2002) . This hypothesis is supported by our previous findings that a mixture of three EET regioisomers inhibited HVSM cell proliferation, and when added in conjunction with CDU, the regioisomer mixture reduced proliferation in these cells further (Davis et al., 2002) . Given the results obtained with novel sEH inhibitors described above, we reinvestigated this hypothesis.
We first retested the preparation of EETs used in the earlier study and found that this preparation still inhibited HVSM proliferation (data not shown). However, LC-MS analysis showed that over time 99% of these EETs had been converted to DHETs, suggesting that the epoxides were not the factor responsible for the anti-proliferative effect. To confirm this hypothesis, we used a mix of EET regioisomers recently produced in our laboratory as well as individual EET regioisomers purchased commercially the earlier EET mixture is not due to DHET since we did not find a correlation between the DHET content of the initial EETs preparation and its activity. These data are consistent with observation described above that the action of CDU is independent of sEH inhibition.
Since both our newly synthesized EETs and two commercially purchased EET regioisomers did not inhibit proliferation, we then decide to test the hypothesis that our initial EETs preparation contains an impurity that is responsible for its anti-proliferative
properties. The purity of these mixtures had been previously assessed by both HPLC/MS and 1 H-NMR, and the mixtures were found to be >98% pure. However, during the initial synthesis, toluene had been used to azeotrope residual acetic acid in the HPLC purified EET isomer fractions. More recently, pentane extraction has been used to remove the EETs from the water/methanol based HPLC solvent, and constituted the single procedural difference between the EET synthesis within our laboratory. Therefore, using GC/MS methods, we directly evaluated the residual toluene level in the original EET preparation and assessed the possibility that this trace impurity could be responsible for the reported EET effect on vascular proliferation. From this analysis, the 10mM stock solution of EETs that had been stored in ampoules at -30ºC since synthesis were found to have 0.6 ± 0.1 % toluene by volume. This translates to a concentration of < 0.0005% toluene being introduced into the VSM proliferation assays, and this concentration did not inhibit proliferation ( Figure 3) . Therefore, the source of the anti-proliferative effect reported in our initial study, while not toluene, is unknown.
Cultured HVSM cells lack functional sEH
The differential effects of various sEH inhibitors on HVSM cell proliferation and the lack of a growth inhibitory effect by the sEH substrates, the EETs, led us to investigate whether HVSM cells in culture conditions possess functional sEH. The presence of sEH in HVSM cells was evaluated using three independent assays.
Cell lysate was obtained from both continuously growing HVSM cells, as well as a known sEH-containing human hepatoma cell line HuH7 (as a positive control).
Immunoblotting of both of these lysates, using a monoclonal antibody to human sEH with recombinant human sEH as positive control, showed the absence of an sEH band at the appropriate 58 kDa molecular weight in HVSM cells (Figure 4 ). To confirm this data, the HVSM cell lysate was also immunoblotted using a rabbit anti-mouse sEH antibody (data not shown). This immunoblot showed a different non-specific pattern of bands and did not detect the 65kD sEH band, confirming the this band does not represent an alternate form of sEH.
Since the intracellular concentration of sEH necessary to regulate intracellular EET level is not known, it is possible that sEH could be undetectable in HVSM cells by
immunoblot and yet could still be catalyzing the conversion of EET regioisomers to DHET regioisomers. To address this possibility, we measured sEH specific activity in HVSM cells and HuH7 cells using racemic [ 3 H]-trans-1,3-diphenylpropene oxide (tDPPO) as the substrate (Borhan et al., 1995) . sEH specific activity in HVSM cells was found to be less than 0.06 +/-0.02 nmol/(min.mg) which is the detection limit of the assay, in marked contrast to the control sEH positive HuH7 cell line, which has an sEH activity of 0.16 +/-0.05 nmol/(min.mg). This data confirms the immunoblotting data above.
To further substantiate the lack of sEH enzyme in these HVSM cells, we used a liquid chromatography tandem mass spectrometry method to monitor changes in sEH metabolites in the presence of an sEH inhibitor. The positive conversion of EET to DHET (as indicated by an increased ratio of EET to DHET) would be evidence of the JPET #91876 14 presence of sEH. HVSM and HuH-7 cells were treated with 500nM mixed EET with and without the CDU (1µM) overnight after which cellular lipids were extracted and analyzed. For this assay a non-growth inhibitory dose of CDU (Davis et al., 2002 ) was used to separate the anti-proliferative effect from sEH inhibition. The addition of the sEH inhibitor CDU to these HVSM cells treated with EET did not increase the ratio of EET to DHET in cellular lipids (Figure 5a ), indicating that EETs are not being converted to DHET by sEH in these HVSM cells and further supporting the likelihood that sEH is not expressed in these cells. As expected the ratio of EET to DHET in the sEH positive
HuH7 cells was higher in cells treated with EET and CDU than it was in cells treated
with EETs alone (Figure 5b ). This increase in EET to DHET ratio in CDU treated HuH7 cells demonstrates that CDU inhibits sEH activity in these cells at 1µM. To our knowledge this is the lowest concentration of an sEH inhibitor that has been used to inhibit its target enzyme in cell culture.
DISCUSSION
In this study, we reproduce the inhibition of HVSM cell proliferation by CDU as we have previously reported (Davis et al., 2002) . However, while we have yet to ascertain the precise mechanism of its vascular anti-proliferative effects, we show that CDU action is not mediated by sEH inhibition or stabilization of EETs in this system.
Our finding that a disubstituted urea compound has substantial and important biological properties, independent of its effect on sEH, suggests that there may exist other uses of this class of compounds which are unrelated to their effects on the epoxyeicosanoids.
The effects of both EETs and the inhibition of sEH on proliferation in cultured mammalian cells are variable. EETs increase proliferation in human umbilical vein endothelial cells (Potente et al., 2003) , pig VSM cells (Fang et al., 1998) , rat mesangial cells (Harris et al., 1990) , rat cerebral capillary endothelial cells (Zhang and Harder, 2002 ) and pig renal epithelial cells (Chen et al., 1998) , all while in culture conditions.
EETs have no effect on proliferation in cultured bovine VSM cells (Sun et al., 2002) , and we now show that EETs do not effect proliferation in human aortic VSM cells. Inhibition of sEH with 4-PCO potentiated EET increased proliferation in pig VSM cells (Fang et al., 1998) , and the sEH inhibitor CDU inhibits proliferation in human VSM cells, aortic ECs, and foreskin fibroblasts (Davis et al., 2002) . Our findings in this study demonstrate that, in marked contrast to CDU, the sEH inhibitors CDUA, ADU, ADUA-BE and 950 do not affect proliferation in HVSM cells.
These cell and species specific variation in proliferative responses to EET and sEH inhibitors may be due to normal variation in sEH expression in these cell types or an artifact of cell culture. Data from our and other laboratories have revealed sEH expression or activity in intact kidney arterioles (Yu et al., 2004) , human saphenous vein, and human aorta (Yu et al., 2004) . Furthermore, in the kidney, sEH expression is localized to the smooth muscle cell layer of the afferent renal arteriole (Yu et al., 2004) , a finding which may help explain the antihypertensive effects of sEH inhibitors. In light of the current study and another study showing that cultured saphenous vein endothelial and VSM cells lack sEH activity (Yu et al., 2004) , it is possible that sEH expression is gradually abolished during the process of cell culture.
Our finding that the sEH inhibitor CDU attenuates proliferation in HVSM cells independently of sEH may lead to re-interpretation of some of the extant data from other such studies using sEH inhibitors in cell culture systems. It may be possible to avoid these sEH independent effects by using sEH inhibitors at lower concentrations. In this study we demonstrate that CDU inhibits sEH activity in cultured cells at 1µM. To our knowledge this is the lowest concentration of an sEH inhibitor that has been used to inhibit its target enzyme in cell culture. It is unlikely that the sEH independent effects of CDU contributed to results of past in vivo studies from our laboratory (Imig et al., 2002; Zhao et al., 2004) since the plasma concentration of CDU in those studies is more than 50 fold lower than the growth inhibitory dose we report in this study. Additionally, concentrations that inhibit proliferation in HVSM cells (Fang et al., 2005) suggest that the mechanism by which CDU elicits its anti-proliferative effect is unrelated to PPARα activation.
A possible explanation for the anti-proliferative effect of CDU is the presence of a heretofore undetected impurity in CDU that is not in present in the other sEH inhibitor preparations. While we can not rule out this possibility, evidence suggests that an impurity is not the cause of this anti-proliferative effect. First, data from another study demonstrates that an inhibitor of sEH not tested for its inhibitory effects in this study (AUDA), inhibits HVSM cell proliferation to a similar extent as some of us (C.M. and B.D.H., submitted) have found with CDU. Second, both inhibitors with anti-proliferative effects and those without were synthesized in our laboratory using similar methodology.
Correlating the different effects of various sEH inhibitors on HVSM proliferation with their structural differences might allow us to predict sEH independent effects in the next generation sEH inhibitors, but as yet, we have not been successful in deducing such a correlation. While CDU inhibits proliferation, we observed in this study that the addition of an acid group to dodecyl carbon chain (CUDA) abolishes this effect.
Likewise, changing the cyclohexyl group to an adamantyl group (ADU) leaving the dodecyl tail alone also abolished the anti-proliferative properties of CDU. Lastly, shortening the carbon chain to two carbons (CEU) abolishes the anti-proliferative properties of CDU (Figure 1b) . Investigation of such structure-activity relationship continues to be an area of active investigation in our laboratories.
Further research on urea based inhibitors of sEH may uncover clinically useful properties of these compounds independent from their effects on sEH activity. In addition to hypertension and inflammation, VSM proliferation is a major contributor to the processes of atherosclerosis and angioplasty restenosis. Since inhibition of sEH lowers blood pressure and reduces inflammation, compounds that attenuate VSM cell proliferation and inhibit sEH would theoretically be ideal anti-atherosclerosis drugs.
Although CDU fits in this class of agents, its pharmaceutical utility is limited by its hydrophobicity. On the other hand, future structural alterations of CDU in order to produce novel orally available compounds, while maintaining their ability to inhibit both sEH and VSM proliferation, would be excellent candidates for novel anti-atherosclerotic pharmaceuticals.
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EETs do not inhibit human VSM cell proliferation.
Human VSM cells were grown to 90% confluence, serum-starved for 1 day and stimulated with PDGF-BB (30 ng/ml). Immediately following stimulation (within 2 min), (a) a mixture of EETs from our laboratory, or (b) the 11,12 EET or 14,15 EET regioisomers from Cayman Chemical were added to the cells at the concentrations shown
After an additional 18 h, thymidine incorporation into DNA was assessed as described in Materials and Methods. Each condition is normalized to PDGF control within the same plate and then analyzed for significance using each plate as a blocking variable in a repeated measures two-way ANOVA. "n" equals at least 6 for each condition. Error bars represent standard deviation. *p < 0.05 compare to PDGF alone. 
